Clinical trials: Leucovorin
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
- Trial name
- NCT03563170
- Testing
- ETBX-011, GI-4000, haNK for infusion
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Gastric Carcinoma Stage IV
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced…
- Trial name
- NCT01748851
- Testing
- XELOX, FOLFOX
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Dong-A University Hospital
Gestational Trophoblastic Neoplasms
Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms
Gestational trophoblastic neoplasm affect women and is sensitive to chemotherapy especially methotrexate and the investigators try to find a role of surgery plus methotrexate instead of multiple doses and cycles of chemotherapy.
- Trial name
- SVCGTN (NCT02606539)
- Testing
- Total abdominal hysterectomy and methotrexate, Methotrexate plus folinic acid alone
- Where
- 2 sites in Egypt
- Volunteers
- 20 people
- Sponsor
- Maher elesawi kamel elesawi
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
This randomized phase II trial studies how well veliparib or pembrolizumab work with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or…
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Trial name
- NCT02921256
- Testing
- Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy
- Where
- 650 sites in United States, Puerto Rico
- Volunteers
- 363 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Induction FLOT With CROSS CRT for Esophageal Cancer
This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin…
- Trial name
- NCT04028167
- Testing
- Sequential FLOT followed by chemoradiation
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Folfox+Irinotecan+Chemort In Esophageal Cancer
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer…
- Trial name
- NCT04656041
- Testing
- FOLFOX/ nal-IRI, Paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Gastric Cancer
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in…
- Trial name
- FIGHT (NCT03694522)
- Testing
- Bemarituzumab, Modified FOLFOX6
- Where
- 189 sites in United States, Australia and 16 more
- Volunteers
- 155 people
- Sponsor
- Five Prime Therapeutics, Inc.
Esophageal Cancer
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
This trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer…
- Trial name
- NCT06452602
- Testing
- Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy, Induction immunochemotherapy followed by concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer
Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer
The rationale of the NEO-FLOT-trial consists of an intensification of the neoadjuvant treatment. This strategy is based upon the clear advantage of perioperative treatment and the fact, that in former trials adjuvant treatment…
- Trial name
- NCT01160419
- Testing
- Docetaxel 50 mg/m2, 1-hour-Infusion, day 1, Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1, Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colorectal Cancer
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and…
- Trial name
- NCT01478594
- Testing
- Tivozanib, Bevacizumab, mFOLFOX6
- Where
- 73 sites in United States, Australia and 10 more
- Volunteers
- 265 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Acute Kidney Injury, Drug Toxicity
Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate
This retrospective observational study will evaluate high-dose methotrexate patterns of use, supportive care measures used during high-dose methotrexate chemotherapy, along with the incidence of delayed elimination of…
- Trial name
- NCT05899751
- Testing
- High-dose methotrexate, Glucarpidase
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Protherics Medicines Development Limited
Rectal Cancer
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
- Trial name
- BRANCH (NCT01481545)
- Testing
- Radiation therapy, Oxaliplatin, Raltitrexed
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute, Naples
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been previously treated.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00025337
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastasis
A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer
To investigate whether intraoperative intraportal chemotherapy combined with adjuvant chemotherapy as treatment could improve disease-free survival (DFS) in patients with curative colorectal cancer resection compared with…
- Trial name
- NCT02402972
- Testing
- FUDR +oxaliplatin, oxaliplatin+Leucovorin+5-FU
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Xu jianmin
Metastatic Breast Cancer
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
The purpose of the study is to determine if eniluracil/5-FU/leucovorin in metastatic breast cancer (MBC) may have efficacy and tolerability advantages over capecitabine monotherapy.
- Trial name
- NCT01231802
- Testing
- Eniluracil, 5-Fluorouracil, Leucovorin
- Where
- 16 sites in United States, Russia
- Volunteers
- 140 people
- Sponsor
- Adherex Technologies, Inc.
Hepatocellular Carcinoma
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in neoadjuvant of resectable Hepatocellular Carcinoma.
- Trial name
- NCT06512467
- Testing
- Donafenib, Sintilimab, HAIC
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreas Neoplasms
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas.
- Trial name
- DOVIPA (NCT06757244)
- Testing
- Dostarlimab, Vitamin D3 (Cholecalciferol), mFOLFIRINOX Treatment Regimen
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- Hopital Foch
Pancreatic Cancer Resectable
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.
This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.
- Trial name
- NCT04224402
- Testing
- mFOLFORINOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yuhong Li
Metastatic Colon Cancer, Stage III Colon Cancer
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer.
- Trial name
- NCT03803553
- Testing
- FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.